Canakinumab for treatment of adult-onset still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial - Kedor, Claudia; Listing, Joachim; Zernicke, Jan; Weiß, Anja; Behrens, Frank; Blank, Norbert; Henes, Jörg Christoph; Kekow, Jörn; Rubbert-Roth, Andrea; Schulze-Koops, Hendrik; Seipelt, Eva; Specker, Christof; et al. (Annals of the rheumatic diseases, 2020)
Gesehen am 29.10.2020